Benzinga | Sep 29, 2020 11:23AM EDT

Evercore ISI Group Initiates Coverage On Spero Therapeutics with Outperform Rating, Announces Price Target of $70

Evercore ISI Group analyst Josh Schimmer initiates coverage on Spero Therapeutics (NASDAQ:SPRO) with a Outperform rating and announces Price Target of $70.